Malignant Mesothelioma Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Malignant Mesothelioma Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global malignant mesothelioma therapeutics market. The report identifies the key trends shaping and driving the global malignant mesothelioma therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global malignant mesothelioma therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global (the US, the UK, France, Germany, Italy, Spain, Japan) malignant mesothelioma therapeutics market was valued at $165m in 2010 and is forecast to grow at a compound annual growth rate (CAGR) of 4.1% to reach $218m by 2017. The current malignant mesothelioma therapeutics market is dominated by the chemotherapeutic regimen, Alimta (pemetrexed), which is a folate antimetabolite in combination with cisplatin. The expected launch of NGR-hTNF (combination of a tumour homing peptide (NGR) with the human tumour necrosis factor (hTNF), Onconase(ranpirnase) and Zolinza (vorinostat) for the second-line treatment in 2014 will drive the market. However, the patent expiry of Alimta in the forecast period will off-set the growth rate.

Scope

The report provides information on the key drivers and challenges of the malignant mesothelioma therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) malignant mesothelioma therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as Tyrosine kinases inhibitor, VEGF inhibitor, Immunomodulators.
- Analysis of the current and future competition in the seven key countries of the malignant mesothelioma therapeutics market. Key market players covered are MolMed S.p.A, Merck and Co., Inc, Tamir Biotechnology Inc., Oxford Biomedica Plc, Canbas Co. Ltd, Bionomics Ltd, and Eisai Co.Ltd.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the malignant mesothelioma therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements malignant mesothelioma therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global malignant mesothelioma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global malignant mesothelioma therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global malignant mesothelioma therapeutics market landscape? – Identify, understand and capitalize.

Table Of Contents

1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Malignant Mesothelioma Therapeutics - Introduction 6
2.1 Disease Overview 6
2.2 Types of Malignant Mesothelioma 6
2.2.1 Based on the Affected Organs 6
2.2.2 Based on the Type of Histology: 6
2.3 Epidemiology 7
2.4 Etiology and Pathophysiology 7
2.5 Symptoms 8
2.6 Prognosis 8
2.7 Diagnosis 9
2.8 Staging and Treatment options 10
2.9 Treatment Options 11
2.10 GlobalData Pipeline Report Guidance 12
3 Malignant Mesothelioma Therapeutics - Market Characterization 13
3.1 Malignant Mesothelioma Therapeutics Market Size, Global, 2005-2010 13
3.2 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - Global 14
3.3 Malignant Mesothelioma Therapeutics Market Size (2005-2010) - The US 15
3.4 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - The US 16
3.5 Malignant Mesothelioma Therapeutics Market Size (2005-2010) - The UK 17
3.6 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - The UK 18
3.7 Malignant Mesothelioma Therapeutics Market Size (2005-2010) - France 19
3.8 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - France 20
3.9 Malignant Mesothelioma Therapeutics Market Size (2005-2010) - Germany 21
3.10 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - Germany 22
3.11 Malignant Mesothelioma Therapeutics Market Size (2005-2010) - Italy 23
3.12 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - Italy 24
3.13 Malignant Mesothelioma Therapeutics Market Size (2005-2010) - Spain 25
3.14 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - Spain 26
3.15 Malignant Mesothelioma Therapeutics Market Size (2005-2010) - Japan 27
3.16 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - Japan 28
3.17 Drivers and Barriers in the Malignant Mesothelioma Therapeutics Market 29
3.17.1 Drivers for the Malignant Mesothelioma Therapeutics Market 29
3.17.2 Barriers to the Malignant Mesothelioma Therapeutics Market 29
3.18 Opportunities and Unmet Needs Analysis 30
3.19 Key Takeaway 30
4 Malignant Mesothelioma Therapeutics - Competitive Assessment 31
4.1 Overview 31
4.2 Strategic Competitor Assessment 31
4.3 Malignant Mesothelioma - Marketed Product Profiles 32
4.3.1 Alimta (pemetrexed) 32
4.4 Key Takeaway 32
5 Malignant Mesothelioma Therapeutics - Pipeline Assessment 33
5.1 Overview 33
5.2 Strategic Pipeline Assessment 33
5.3 Malignant Mesothelioma Therapeutics - Pipeline by Phases of Development 33
5.3.1 Technology Trends Analytical Framework 34
5.3.2 Malignant Mesothelioma Therapeutics - Phase III Pipeline 35
5.3.3 Malignant Mesothelioma Therapeutics - Phase II Pipeline 35
5.3.4 Malignant Mesothelioma Therapeutics - Phase I Pipeline 36
5.3.5 Malignant Mesothelioma Therapeutics - Preclinical Pipeline 36
5.4 Malignant Mesothelioma Therapeutics - Clinical Pipeline by Mechanism of Action 37
5.5 Malignant Mesothelioma Therapeutics - Other Novel Mechanisms of Action 37
5.6 Malignant Mesothelioma Therapeutics - Promising Drugs under Clinical Development 38
5.7 Profiles of Promising Drugs in Clinical Development 38
5.7.1 NGR-hTNF(combination of a tumour homing peptide (NGR) with the human tumour necrosis factor (hTNF) 38
5.7.2 Onconase (ranpirnase) 39
5.7.3 Zolinza (vorinostat) 39
5.8 Key Takeaway 39
6 Malignant Mesothelioma Therapeutics - Clinical Trials Mapping 40
6.1 Clinical Trials by Country 40
6.2 Clinical Trials by Phase 41
6.3 Clinical Trials by Trial Status 42
6.4 Clinical Trials by Overall Sponsors 43
6.5 Top Companies Participating in Therapeutics Clinical Trials 44
7 Malignant Mesothelioma Therapeutics - Strategic Assessment 45
7.1 Key Events Impacting the Future Market 45
7.2 Implications for Future Market Competition 46
8 Malignant Mesothelioma Therapeutics - Future Players 47
8.1 Introduction 47
8.2 Company Profiles 47
8.2.1 MolMed S.p.A 47
8.2.2 Merck and Co. 49
8.2.3 Tamir Biotechnology Inc. (formerly known as Alfacell Corporation) 65
8.3 Malignant Mesothelioma - Other Future Players 67
9 Malignant Mesothelioma Therapeutics - Appendix 69
9.1 Market Definitions 69
9.2 Abbreviations 69
9.3 Research Methodology 70
9.3.1 Coverage 70
9.3.2 Secondary Research 70
9.3.3 Forecasting 70
9.3.4 Primary Research 73
9.3.5 Expert Panel Validation 73
9.4 Contact Us 73
9.5 Disclaimer 73
9.6 Sources 74

List of Tables

Table 1: Staging System of Malignant Mesothelioma 10
Table 2: Malignant Mesothelioma Therapeutics Market, Global, Revenue ($m), 2005-2010 13
Table 3: Malignant Mesothelioma Therapeutics Market, Global, Forecast ($m), 2010-2017 14
Table 4: Malignant Mesothelioma Therapeutics Market, The US, Revenue ($m), 2005-2010 15
Table 5: Malignant MesotheliomaTherapeutics Market, The US, Forecast ($m), 2010-2017 16
Table 6: Malignant Mesothelioma Therapeutics Market, The UK, Revenue ($m), 2005-2010 17
Table 7: Malignant Mesothelioma Therapeutics Market, The UK, Forecast ($m), 2010-2017 18
Table 8: Malignant Mesothelioma Therapeutics Market, France, Revenue ($m), 2005-2010 19
Table 9: Malignant Mesothelioma Therapeutics Market, France, Forecast ($m), 2010-2017 20
Table 10: Malignant Mesothelioma Therapeutics Market, Germany, Revenue ($m), 2005-2010 21
Table 11: Malignant Mesothelioma Therapeutics Market, Germany, Forecast ($m), 2010-2017 22
Table 12: Malignant Mesothelioma Therapeutics Market, Italy, Revenue ($m), 2005-2010 23
Table 13: Malignant Mesothelioma Therapeutics Market, Italy, Forecast ($m), 2010-2017 24
Table 14: Malignant Mesothelioma Therapeutics Market, Spain, Revenue ($m), 2005-2010 25
Table 15: Malignant Mesothelioma Therapeutics Market, Spain, Forecast ($m), 2010-2017 26
Table 16: Malignant Mesothelioma Therapeutics Market, Japan, Revenue ($m), 2005-2010 27
Table 17: Malignant Mesothelioma Therapeutics Market, Japan, Forecast ($m), 2010-2017 28
Table 18: Malignant Mesothelioma Therapeutics, Phase III Pipeline, 2011 35
Table 19: Malignant Mesothelioma Therapeutics, Phase II Pipeline, 2011 35
Table 20: Malignant Mesothelioma Therapeutics, Phase I Clinical Pipeline, 2011 36
Table 21: Malignant Mesothelioma Therapeutics, Preclinical Pipeline, 2011 36
Table 22: Malignant Mesothelioma Therapeutics, Other Mechanisms of Action 37
Table 23: Malignant Mesothelioma Therapeutics - Promising Drugs In Clinical Development, 2011 38
Table 24: Malignant Mesothelioma Therapeutics, Clinical Trials by Country 40
Table 25: Malignant Mesothelioma Therapeutics, Clinical Trials by Phase 41
Table 26: Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Status 42
Table 27: Malignant Mesothelioma Therapeutics, Clinical Trials by Overall Sponsors 43
Table 28: Malignant Mesothelioma Therapeutics -Top Companies Participating in Therapeutics Clinical Trials, 2011 44
Table 29: MolMed S.p.A- Oncology Pipeline , 2011 48
Table 30: MolMed S.p.A - Deals 2009-2011 48
Table 31: Merck and Co. - Oncology Pipeline 51
Table 32: Merck and Co. - Deals 2009-2011 55
Table 33: Tamir Biotechnology - Oncology Pipeline 66
Table 34: Tamir Biotechnology - Deals 2009-2011 66
Table 35: Other Companies that have Molecules in the Pipeline 67

List of Figures

Figure 1: Classification of Malignant Mesothelioma 11
Figure 2: Malignant Mesothelioma Therapeutics Market, Global, Revenue ($m), 2005-2010 13
Figure 3: Malignant Mesothelioma Therapeutics Market, Global, Forecast ($m), 2010-2017 14
Figure 4: Malignant Mesothelioma Therapeutics Market, The US, Revenue ($m), 2005-2010 15
Figure 5: Malignant Mesothelioma Therapeutics Market, The US, Forecast ($m), 2010-2017 16
Figure 6: Malignant Mesothelioma Therapeutics Market, The UK, Revenue ($m), 2005-2010 17
Figure 7: Malignant Mesothelioma Therapeutics Market, The UK, Forecast ($m), 2010-2017 18
Figure 8: Malignant Mesothelioma Therapeutics Market, France, Revenue ($m), 2005-2010 19
Figure 9: Malignant Mesothelioma Therapeutics Market, France, Forecast ($m), 2010-2017 20
Figure 10: Malignant Mesothelioma Therapeutics Market, Germany, Revenue ($m), 2005-2010 21
Figure 11: Malignant Mesothelioma Therapeutics Market, Germany, Forecast ($m), 2010-2017 22
Figure 12: Malignant Mesothelioma Therapeutics Market, Italy, Revenue ($m), 2005-2010 23
Figure 13: Malignant Mesothelioma Therapeutics Market, Italy, Forecast ($m), 2010-2017 24
Figure 14: Malignant Mesothelioma Therapeutics Market, Spain, Revenue ($m), 2005-2010 25
Figure 15: Malignant Mesothelioma Therapeutics Market, Spain, Forecast ($m), 2010-2017 26
Figure 16: Malignant Mesothelioma Therapeutics Market, Japan, Revenue ($m), 2005-2010 27
Figure 17: Malignant Mesothelioma Therapeutics Market, Japan, Forecast ($m), 2010-2017 28
Figure 18: Opportunity and Unmet Need in the Malignant Mesothelioma Therapeutics Market, 2011 30
Figure 19: Malignant Mesothelioma Therapeutics Market - Strategic Competitor Assessment, 2011 31
Figure 20: Malignant Mesothelioma Therapeutics, Pipeline by Phase of Clinical Development, 2011 33
Figure 21: Malignant Mesothelioma Therapeutics - Technology Trends Analytics Framework, 2011 34
Figure 22: Malignant Mesothelioma Therapeutics - Technology Trends Analytics Framework - Description, 2011 34
Figure 23: Malignant Mesothelioma Therapeutics - Pipeline by Mechanism of Action, 2011 37
Figure 24: Malignant Mesothelioma Therapeutics - Clinical Trials by Country, 2011 40
Figure 25: Malignant Mesothelioma Therapeutics - Clinical Trials by Phase, 2011 41
Figure 26: Malignant Mesothelioma Therapeutics - Clinical Trials by Status, 2011 42
Figure 27: Malignant Mesothelioma Therapeutics - Overall Sponsors, 2011 43
Figure 28: Malignant Mesothelioma Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 44
Figure 29: Malignant Mesothelioma Therapeutics Market, Drivers and Restraints, 2011 45
Figure 30: Malignant Mesothelioma Therapeutics, Implications for Future Market Competition, 2011 46
Figure 31: Malignant Mesothelioma Therapeutics - Pipeline by Company, 2011 47
Figure 32: GlobalData Market Forecasting Model 72

Companies Mentioned

MolMed S.p.A
Merck and Co.
Tamir Biotechnology Inc

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Inflammation - Pipeline Review, H1 2014

Inflammation - Pipeline Review, H1 2014

  • $ 2 500
  • Company report
  • June 2014
  • by Global Markets Direct

Inflammation - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Inflammation - Pipeline Review, H1 2014', provides an overview of the Inflammation's therapeutic pipeline. This report provides ...

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

- Product Pipeline Review - H2 2011” provides a detailed overview on the ImmunoCellular Therapeutics, Ltd.’s research and development focus. The report includes information on current developmental ...

Sarepta Therapeutics, Inc. - Product Pipeline Review - 2014

Sarepta Therapeutics, Inc. - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

Sarepta Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Sarepta Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Sarepta Therapeutics, ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.